NASDAQ:NRSN - Nasdaq - IL0011809592 - Common Stock - Currency: USD
1.09
-0.01 (-0.91%)
The current stock price of NRSN is 1.09 USD. In the past month the price decreased by -3.54%. In the past year, price decreased by -14.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
NEUROSENSE THERAPEUTICS LTD
11 Hamenofim St., Building B
Herzliya IL
Employees: 18
Company Website: https://www.neurosense-tx.com/
Investor Relations: https://www.neurosense-tx.com/investors/
Phone: 97299531142
The current stock price of NRSN is 1.09 USD. The price decreased by -0.91% in the last trading session.
The exchange symbol of NEUROSENSE THERAPEUTICS LTD is NRSN and it is listed on the Nasdaq exchange.
NRSN stock is listed on the Nasdaq exchange.
8 analysts have analysed NRSN and the average price target is 7.65 USD. This implies a price increase of 601.83% is expected in the next year compared to the current price of 1.09. Check the NEUROSENSE THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEUROSENSE THERAPEUTICS LTD (NRSN) has a market capitalization of 25.32M USD. This makes NRSN a Nano Cap stock.
NEUROSENSE THERAPEUTICS LTD (NRSN) currently has 18 employees.
NEUROSENSE THERAPEUTICS LTD (NRSN) has a support level at 1.02 and a resistance level at 1.12. Check the full technical report for a detailed analysis of NRSN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NRSN does not pay a dividend.
NEUROSENSE THERAPEUTICS LTD (NRSN) will report earnings on 2025-03-19, before the market open.
NEUROSENSE THERAPEUTICS LTD (NRSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
The outstanding short interest for NEUROSENSE THERAPEUTICS LTD (NRSN) is 1.01% of its float. Check the ownership tab for more information on the NRSN short interest.
ChartMill assigns a technical rating of 4 / 10 to NRSN. When comparing the yearly performance of all stocks, NRSN turns out to be only a medium performer in the overall market: it outperformed 58.13% of all stocks.
Over the last trailing twelve months NRSN reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 27.17% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -407.98% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to NRSN. The Buy consensus is the average rating of analysts ratings from 8 analysts.